(Q36788485)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Tim Maughan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

503-518

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

Epidermal growth factor-related peptides and their receptors in human malignancies

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

The ErbB receptors and their ligands in cancer: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Critical evaluation of current treatments in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Tyrosine kinase inhibitors-ZD1839 (Iressa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Somatic mutations of epidermal growth factor receptor in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Tissue microarray analysis of EGFR gene amplification and gain in Bulgarian patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Development of strategies for the use of anti-growth factor treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

SRC gene expression in human cancer: the role of transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Targeting signal transduction pathways in colorectal cancer--more than skin deep

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.503

21 January 2018

Identifiers

DOI

10.1586/14737140.7.4.503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428171%20AND%20SRC:MED&resulttype=core&format=json

release_7g3wcmbqmndglljigbqfey5gvm

29 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7g3wcmbqmndglljigbqfey5gvm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference